A simple test to detect fatty liver in people with metabolic syndrome
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests whether a simple blood test can help detect fatty liver disease in people who have metabolic syndrome. It may offer a less invasive way to identify liver problems early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with or are suspected to have metabolic syndrome, which includes central obesity (waist size 94 cm or more for men, 80 cm or more for women) and at least two of the following: high triglycerides, low HDL cholesterol, high blood pressure, or high fasting blood sugar.
- You do not have other liver diseases like viral or autoimmune hepatitis.
- You do not drink more than 20 grams of alcohol per day (men) or 10 grams per day (women).
- You are not pregnant, do not have cancer, and do not have advanced cirrhosis.
- You are not taking medications that affect metabolism, such as steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a digital health app designed to help people with metabolic-associated fatty liver disease (MAFLD). The app provides diet and exercise guidance to improve liver health.
This study is looking for a simple way to detect fat buildup in the liver (fatty liver) using a ratio calculated from your blood creatinine level and your body weight. If you have metabolic syndrome, they want to see if this ratio can predict fatty liver, which may help with earlier detection without needing extra scans.
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study looks at whether a simple blood test (FIB-4) can help detect liver scarring in people with obesity. It may help doctors identify liver problems earlier.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
Hear when a new MAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.